The deal makes DNAVision the first European lab to provide services for low- to medium-density microarray testing, and "completes very well our actual gene expression offer using high density microarray and real time PCR," Jean-François Laes, microarray unit manager at DNAVision, said in a statement.
Financial terms of the deal were not disclosed.
The DualChip platform is used in the US Food and Drug Administration's MAQC (MicroArray Quality Control) project.